World of DTC Marketing

DECEMBER 29, 2020

Both the Pfizer and Moderna vaccines copied RNA sequence from the virus genome and found a way to manufacture it at scale with high-level processes and quality control. These vaccines were developed using different “platform technologies” that involve slotting genetic material from the virus into a tried and tested delivery package.

Vaccination 307

Vaccination Vaccine Development Clinical Trials 307

XTalks

APRIL 1, 2025

Hemophilia A and B are rare genetic bleeding disorders caused by a deficiency or dysfunction of clotting factors VIII (FVIII) and IX (FIX), respectively. Through RNA silencing, it targets the expression of antithrombin, a protein that inhibits blood clotting. Qfitlia will be entering a small but competitive market.

FDA Approval 59

FDA Approval RNA Clinical Trials Clinical Trials 59

XTalks

FEBRUARY 24, 2025

Carlsbad, California-based Ionis Pharmaceuticals announced it will be sharing promising new trial data for its RNA-targeted prophylactic treatment donidalorsen for hereditary angioedema (HAE) at the 2025 American Academy of Allergy, Asthma & Immunology (AAAAI)/World Allergy Organization (WAO) Joint Congress in San Diego, California.

Trials 59

Trials RNA Allergies Drugs 59

pharmaphorum

NOVEMBER 1, 2022

14th Annual RNA Therapeutics. Investigating the next generation of genetic medicine through RNA based therapies. RNA therapeutics is a rapidly expanding industry with increasingly growing potential for immunotherapy, personalised medicines, and treatment of genetic, infectious, and chronic diseases.

RNA 52

RNA Genetics Gene Editing In-Vitro 52

Roots Analysis

AUGUST 17, 2023

Genome sequencing has historically been classified into DNA sequencing and RNA sequencing. There are several RNA sequencing service providers coming in this market. Due to lack of in-house RNA sequencing facilities, many stakeholders are dependent on service provider, leads to rise demand of RNA sequencing services.

RNA 52

RNA DNA Genome Genomics 52

pharmaphorum

MAY 14, 2021

Biogen has made a further push into RNA-based drug discovery via a collaboration with Envisagenics, which applies artificial intelligence RNA sequencing data to discover new drug targets and therapeutics. At least 370 genetic disorders are known to derive from errors introduced during this splicing process.

RNA 60

RNA Licensing Licensing Genetics 60

Pharmaceutical Technology

JANUARY 12, 2023

Under the research partnership deal, the companies will develop new precision genetic medicines for a severe form of genetic dilated cardiomyopathy (DCM). We believe the advanced RNA technology and human disease models of Phlox Therapeutics perfectly partner with the delivery tools Solid Biosciences brings to this collaboration.”.

RNA 130

RNA Gene Therapy Genetics Genetic Disease 130

Pharmaceutical Technology

MARCH 28, 2023

The system comprises the Cas9 enzyme and a guide RNA. Vertex Pharmaceuticals Cell and Genetic Therapies chief and executive vice-president Bastiano Sanna said: “We have multiple programmes in our T1D portfolio including VX-880 and VX-264, which are in the clinic, as well as our hypoimmune programme, in preclinical development.

Gene Editing 235

Gene Editing DNA Gene Gene Therapy 235

Pharmaceutical Technology

DECEMBER 14, 2022

GSK has entered a strategic partnership with Wave Life Sciences to progress the discovery and development of oligonucleotide therapies for new genetic targets. The alliance will merge the PRISM oligonucleotide platform of Wave and the capabilities of GSK in genetics and genomics.

Life Science 162

Life Science Development Gene Therapy Genetics 162

XTalks

DECEMBER 22, 2021

The RNA Revolution: From mRNA Vaccines to RNA Editing. The age of RNA is officially here, and it’s here to stay as more than a passing life science trend. The market for mRNA-based vaccines and therapeutics is projected to grow from $46.7 RNA technology is not new nor has its potential been surprising.

Life Science 98

Life Science RNA Vaccination Vaccine 98

Pharma Marketing Network

DECEMBER 21, 2020

Almost two decades after the human genome was sequenced, a trickle of new genetic medicines (i.e., those that modify the expression of an individual’s genes or repair abnormal genes) has entered clinical practice, including 11 RNA therapeutics, 2 in vivo gene therapies, and 2 gene-modified cell therapies.

Genetics 52

Genetics Medicine Gene Therapy Marketing 52

Roots Analysis

OCTOBER 22, 2023

RNA therapeutics are a novel class of biopharmaceuticals that harness the power of RNA molecules for the treatment and prevention of a wide range of disorders, including oncological, and genetic disorders as well as infectious diseases. Non-coding RNAs include antisense oligonucleotides (ASOs) and RNA aptamers.

RNA 40

RNA Protein Genetics Gene Expression 40

pharmaphorum

JANUARY 10, 2022

Previously, messenger RNA (mRNA) therapies were a niche part of the global R&D pipeline, now a wide section of the public is at least familiar with the name of this type of therapy. The company has also stated, at the same time as the study was announced, that it will look at developing mRNA technology in oncology and genetic diseases.

RNA 111

RNA Vaccination Vaccine Pharma Companies 111

Roots Analysis

FEBRUARY 23, 2022

Presently, a variety NGS kits, including sample extraction kit, library preparation kit, amplification kit, purification kit and quantification kit, are available in the market. NGS Library Preparation Kits Market. Currently, close to 60 industry players are actively offering NGS kits for preparing DNA / RNA libraries.

Genetics 52

Genetics DNA RNA Reagent 52

pharmaphorum

DECEMBER 13, 2021

One of its other scientific legacies was the specific development and approval of mRNA vaccines, the first in that drug class on the market. Since their launch, they have dominated the Covid-19 vaccine market due to their first-to-market status, efficacy and safety profiles and manufacturing success. It may have sold its 7.7%

RNA 105

RNA Vaccination Vaccine Development 105

Roots Analysis

OCTOBER 30, 2023

In the past few years, Next Generation RNA therapeutics have emerged as one of the key therapeutic modalities in the modern healthcare industry. These RNA based therapeutics play a crucial role in protein production and regulation of gene functions.

RNA 40

RNA Vaccination Vaccine Development 40

pharmaphorum

DECEMBER 1, 2020

The filing for a conditional marketing authorisation completed the rolling submission process that began on October 6. The EMA has also confirmed it has received a filing from Moderna, which is producing a rival vaccine based on similar RNA technology.

Vaccination 88

Vaccination Vaccine RNA Clinical Trials 88

Pharmaceutical Technology

FEBRUARY 23, 2023

The collaboration will combine the mRNA platform of Moderna with the gene editing technologies suite, including the base editing capabilities of Life Edit for the development of curative therapies to treat challenging genetic diseases.

Gene Editing 147

Gene Editing Gene In-Vivo Gene Therapy 147

Roots Analysis

FEBRUARY 21, 2022

These kits require less input sample, produce sufficient DNA / RNA libraries with minimum errors and are compatible with a broad range of input samples, including blood, cells, plasma and saliva. The various advantages of NGS are briefly described below: Next Generation Sequencing (NGS) Library Preparation Kits Market – Roots Analysis.

Marketing 52

Marketing Gene Sequencing DNA Genome 52

BioPharma Reporter

JULY 21, 2022

US biotech, CAMP4 Therapeutics, has secured US$100m in a Series B financing round that it says will be used to accelerate expansion of its regulatory RNA (regRNA) platform.

Genetic Disease 52

Genetic Disease RNA Genetics Regulation 52

Worldwide Clinical Trials

MAY 30, 2024

Since marketing authorization for the first breakthrough treatment in 1994, the steady increase in clinical trials reflects the community’s commitment to finding effective ALS treatments despite the numerous hurdles associated with clinical trial design, from proof-of-concept to pivotal trials. Director, Therapeutic Area Medical Lead.

Gene 204

Gene Clinical Trials Clinical Trials Gene Therapy 204

Roots Analysis

AUGUST 15, 2024

This article explores the role of molecular diagnostics in early cancer detection, highlighting the benefits and future prospects in the oncology molecular diagnostics market. A growing sub-segment of the overall market is oncology molecular diagnostics market, which is helping fill the unmet need for early diagnosis.

Marketing 40

Marketing Genetics Genome Genomics 40

XTalks

DECEMBER 13, 2023

Related: Top 30 Pharma Companies in 2023: Statistics and Trends 1) Moderna Compound annual growth rate: 415 percent Moderna, headquartered in Massachusetts, is a prominent biotechnology company specializing in RNA therapeutics, particularly mRNA vaccines. vaccine, mRNA-1273.815.

Genetics 111

Genetics Vaccination Vaccine DNA 111

Roots Analysis

MARCH 16, 2023

It is important in the process of protein synthesis because mRNA is responsible for transferring genetic information from DNA to ribosomes, which then decodes the genetic information into a protein. Messenger ribonucleic acid (mRNA) is a single-stranded molecule that is complementary to a gene’s DNA.

Vaccination 52

Vaccination Vaccine DNA Protein 52

pharmaphorum

OCTOBER 12, 2022

David Del Bourgo (CEO and co-founder, Whitelab Genomics) has always been passionate about introducing disruptive, innovative technologies to markets. We thought, there has to be something to help use data to make [drug developers] more efficient in bringing therapies to market faster, and at a lower price,” Del Bourgo explains.

Genome 105

Genome Genomics Medicine Development 105

pharmaphorum

JANUARY 6, 2021

It’s likely no coincidence that Pfizer’s flagship project in 2020 while the design of the logo was being finalised was unquestionably its high-profile alliance with BioNTech on the RNA-based coronavirus vaccine Comirnaty, which provided further evidence of the potential of harnessing genetic toolkits to tackle health issues.

DNA 116

DNA Branding Vaccine Vaccination 116

Roots Analysis

AUGUST 12, 2024

These diagnostic solutions are essential for detecting and monitoring diseases, identifying genetic abnormalities, and guiding personalized treatment plans. Molecular diagnostic solutions are pivotal across various medical fields, including oncological disorders, infectious diseases, genetic testing, and personalized medicine.

Genetics 40

Genetics Gene Expression RNA DNA 40

XTalks

JANUARY 3, 2024

Amvuttra: Alnylam’s Similar Treatment on the Market In 2022, Alnylam, a US-based biopharma company with expertise in RNA interference therapeutics for genetically defined diseases, received FDA approval for its drug Amvuttra (vutrisiran) for the treatment of hATTR.

FDA Approval 105

FDA Approval Protein RNA Clinical Trials 105

The Pharma Data

MAY 31, 2022

Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Takeda ( TSE:4502/NYSE:TAK ) announced to transfer the marketing authorization in Japan for Moderna’s COVID-19 vaccine Spikevax TM (mRNA-1273) from Takeda to Moderna in Japan as of August 1, 2022. “We Moderna, Inc., About Moderna.

Vaccination 52

Vaccination Vaccine Marketing RNA 52

Roots Analysis

FEBRUARY 13, 2023

It transfers genetic information form to DNA to ribosomes, a specialized structure, or organelle, which decodes genetic information into a protein. With the help of genetic engineering, synthetic mRNAs can express proteins, as they structurally resemble a natural mRNA.

Manufacturing 52

Manufacturing Drug Delivery Systems Genetic Engineering RNA 52

Delveinsight

JANUARY 18, 2021

Angelman syndrome (AS) is a complex genetic rare disorder that affects the nervous system. The present Angelman syndrome treatment market revolves around the management of symptoms rather than curing the condition. . However, the journey to secure the FDA nod in the Angelman syndrome market landscape does not seem to be all flowery.

Marketing 52

Marketing Gene Drugs Protein 52

pharmaphorum

DECEMBER 21, 2020

Their technology is based on synthetic messenger RNA – short for ribose nucleic acid – which is a short transcript of a longer DNA code. As it’s just a messenger molecule, it does not affect the body’s own genetic code when it is injected as a vaccine – but what it does do is instruct cells to code for copies of a certain protein.

Vaccination 111

Vaccination Vaccine Doctors Doctor 111

pharmaphorum

OCTOBER 21, 2021

Givlaari (givosiran) has been recommended as a treatment option for people aged 12 and over with AHP, a rare life-threatening genetic condition that causes attacks of severe abdominal pain, vomiting and nervous system disorders, such as seizures, depression and anxiety.

Gene Silencing 98

Gene Silencing Gene RNA Drugs 98

XTalks

OCTOBER 26, 2023

variant was selected in June and within a few months, both Pfizer-BioNTech and Moderna were able to get vaccines for it to market by September, which Dr. Kierstead says is “astonishingly fast.” The Flu versus COVID-19: Virology and Vaccines SARS-CoV-2 versus Influenza Virology Viruses contain genetic material that can either be RNA or DNA.

Vaccination 105

Vaccination Vaccine RNA Manufacturing 105

pharmaphorum

DECEMBER 23, 2020

2020 also saw some of the first “tumour agnostic” cancer drugs get to market, with Bayer’s Vitravki (larotrectinib) getting funding in the UK for tumours with confirmed neurotrophic tyrosine receptor kinase (NTRK) gene fusions.”.

Marketing 96

Marketing Gene Gene Silencing Drugs 96

pharmaphorum

SEPTEMBER 21, 2020

A group of rare genetic disorders, FCS affects between 55 and 110 people in England and causes very high levels of triglyceride fat in the blood. Akcea – an affiliate of Ionis that is set to become a wholly-owned subsidiary shortly – specialises in antisense drugs that target RNA to prevent the expression of errant genes that cause diseases.

Drugs 80

Drugs RNA Medicine Genetics 80

pharmaphorum

NOVEMBER 24, 2020

The FDA has approved Alnylam’s gene silencing drug Oxlumo, the first treatment for primary hyperoxaluria type 1 (PH1), an ultra-rare and life-threatening genetic disorder. Oxlumo (lumasiran) was also approved in the European Union last week, making it the third from Alnylam’s pipeline of RNA interference therapeutics to make it to market.

FDA Approval 52

FDA Approval Gene Silencing Drugs RNA 52